This model allowed us to study TP53-mediated responses to DNA damage and cell cycle regulation, providing deeper insights into the therapeutic potential of targeting RNPC3. However, while we were successful in demonstrating the wide applicability of our results across a variety of in vivo and in vitro cancer models, there are also disadvantages to our multifaceted approach. This evidence concerns the gene RNPC3 and cancer.